Similar articles

• [Thrombocytosis of mechanical prosthetic heart valves is al life-threatening condition. Thrombocyte inhibition possible as treatment and prevention].

  Stenudd J, Linder R. Stenudd J, et al. Lakartidningen. 2011 May 4-10;108(18):988-91. Lakartidningen. 2011. PMID: 21809526 Review. Swedish. No abstract available.
• Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic.

  Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T. Cortelazzo S, et al. Thromb Haemost. 1993 Apr 1;69(4):316-20. Thromb Haemost. 1993. PMID: 8497842
• Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue.

  Colli A, Verhoye JP, Leguerrier A, Gherli T. Colli A, et al. Eur J Cardiothorac Surg. 2007 Apr;31(4):573-7. doi: 10.1016/j.ejcts.2007.02.002. Epub 2007 Feb 21. Eur J Cardiothorac Surg. 2007. PMID: 17317197 Review.
• eComment: Freedom from complications related to dual ball-and-cage mechanical valve prostheses despite thirty years without anticoagulation.

  Bockeria LA, Skopin II, Kuts EV. Bockeria LA, et al. Interact Cardiovasc Thorac Surg. 2008 Dec;7(6):1169. doi: 10.1510/icvts.2007.172155A. Interact Cardiovasc Thorac Surg. 2008. PMID: 19029395 No abstract available.
• Successful use of fondaparinux early after mechanical aortic valve replacement in a patient with a history of heparin-induced thrombocytopenia.

  Willenborg KL. Willenborg KL. Pharmacotherapy. 2014 Jun;34(6):e55-9. doi: 10.1002/phar.1416. Epub 2014 Mar 19. Pharmacotherapy. 2014. PMID: 24644124